Macquarie Group
RCEL icon

Macquarie Group’s Avita Medical RCEL Stock Holding History

Macquarie Group’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$886K Sell
75,492
-68,672
-48% -$544K ﹤0.01% 668
2026
Q2 		$595K Buy
144,164
+132,262
+1,111% +$570K ﹤0.01% 700
2026
Q1 		$44K Buy
11,902
+10,145
+577% +$42.6K ﹤0.01% 796
2025
Q4 		$6.06K Sell
1,757
-19,692
-92% -$78.6K ﹤0.01% 834
2025
Q3 		$110K Sell
21,449
-4,677
-18% -$24.4K ﹤0.01% 1518
2025
Q2 		$138K Buy
+26,126
New +$190K ﹤0.01% 1561
2025
Q1 		– Sell
-623
Closed -$8 – 1781
2024
Q4 		$8 Sell
623
-241
-28% -$2.84K ﹤0.01% 1659
2024
Q3 		$9.26K Sell
864
-3,437
-80% -$32.3K ﹤0.01% 1630
2024
Q2 		$34.1K Buy
4,301
+3,318
+338% +$31.6K ﹤0.01% 1618
2024
Q1 		$16 Buy
983
+52
+6% +$842 ﹤0.01% 1705
2023
Q4 		$12.8K Sell
931
-910
-49% -$10.4K ﹤0.01% 1617
2023
Q3 		$26 Sell
1,841
-1,595
-46% -$27K ﹤0.01% 1644
2023
Q2 		$58.4K Sell
3,436
-892
-21% -$13.1K ﹤0.01% 1610
2023
Q1 		$60.5K Buy
+4,328
New +$46K ﹤0.01% 1630
2022
Q1 		– Sell
-26,176
Closed -$314K – 2639
2021
Q4 		$314K Sell
26,176
-5,700
-18% -$86.9K ﹤0.01% 1695
2021
Q3 		$565K Buy
31,876
+22,852
+253% +$431K ﹤0.01% 1670
2021
Q2 		$185K Buy
9,024
+8,448
+1,467% +$166K ﹤0.01% 1820
2021
Q1 		$11K Sell
576
-8,305
-94% -$193K ﹤0.01% 2382
2020
Q4 		$165K Sell
8,881
-3,406
-28% -$74.7K ﹤0.01% 1728
2020
Q3 		$375K Buy
+12,287
New +$306K ﹤0.01% 1474

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Macquarie Group's RCEL Position: Q3 2026 in Review

Macquarie Group reduced its Avita Medical (RCEL) stake by 48% in Q3 2026, selling an estimated $544K and leaving 75,492 shares worth $886K. The position accounts for ﹤0.01% of the portfolio, ranked #668.

Macquarie Group first reported a position in RCEL in Q3 2020 and has held it in 20 quarters since. 58 funds tracked by Wall St. Rank hold RCEL as of Q3 2026.

  • Macquarie Group held 75,492 shares of Avita Medical worth $886K as of Q3 2026.
  • Macquarie Group sold 68,672 Avita Medical shares in Q3 2026, an estimated $544K.
  • Avita Medical made up ﹤0.01% of Macquarie Group's portfolio in Q3 2026, its #668 holding.
  • Macquarie Group first reported a position in Avita Medical in Q3 2020 and has held it in 20 quarters since.
  • 58 funds tracked by Wall St. Rank held Avita Medical as of Q3 2026.

Based on Macquarie Group's 13F filing for Q3 2026, filed 13 Nov 2026.